Ready, AIM, stop: ibrutinib plus venetoclax in MCL
- PMID: 39172439
- DOI: 10.1182/blood.2024025021
Ready, AIM, stop: ibrutinib plus venetoclax in MCL
Comment on
-
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388. Blood. 2024. PMID: 38662991 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources